Replies to post #655 on Vascular Biogenics Ltd (VBLT)

[gr8db8]

1) Still in the very early stages.

2) "MOSPD2 promotes metastasis of breast cancer cells and is a potential target for the treatment of metastatic breast cancer." Obviously, this is a huge population and if VBLT can create something that prevents cancer cell motility, then all the better!

[gr8db8]

Here is the full research:
http://www.jimmunol.org/content/jimmunol/198/5/2125.full.pdf

"Results were in line with our previous findings: BIO-VB-201 and BIO-VB-221
bound similarly to TLR-2, whereas MOSPD2 precipitated only with BIO-VB-201 (Fig. 1E). We therefore hypothesized that MOSPD2 promotes monocyte migration and that VB-201 may inhibit MOSPD2 function."